400 related articles for article (PubMed ID: 17175012)
1. Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets.
Cimbaluk D; Rotmensch J; Scudiere J; Gown A; Bitterman P
Gynecol Oncol; 2007 Apr; 105(1):138-44. PubMed ID: 17175012
[TBL] [Abstract][Full Text] [Related]
2. COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?
Raspollini MR; Susini T; Amunni G; Paglierani M; Taddei A; Marchionni M; Scarselli G; Taddei GL
Gynecol Oncol; 2005 Jan; 96(1):159-67. PubMed ID: 15589595
[TBL] [Abstract][Full Text] [Related]
3. EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.
Livasy CA; Reading FC; Moore DT; Boggess JF; Lininger RA
Gynecol Oncol; 2006 Jan; 100(1):101-6. PubMed ID: 16157366
[TBL] [Abstract][Full Text] [Related]
4. Expression of c-kit in uterine carcinosarcoma.
Menczer J; Kravtsov V; Levy T; Berger E; Glezerman M; Avinoach I
Gynecol Oncol; 2005 Jan; 96(1):210-5. PubMed ID: 15589603
[TBL] [Abstract][Full Text] [Related]
5. COX-2 expression in uterine carcinosarcoma.
Menczer J; Schreiber L; Sukmanov O; Kravtsov V; Berger E; Golan A; Levy T
Acta Obstet Gynecol Scand; 2010; 89(1):120-5. PubMed ID: 19900134
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical analysis of carcinomatous and sarcomatous components in the uterine carcinosarcoma: a case report.
Semczuk A; Skomra D; ChyzyĆska M; Szewczuk W; Olcha P; Korobowicz E
Pathol Res Pract; 2008; 204(3):203-7. PubMed ID: 18207653
[TBL] [Abstract][Full Text] [Related]
7. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma.
Emoto M; Charnock-Jones DS; Licence DR; Ishiguro M; Kawai M; Yanaihara A; Saito T; Hachisuga T; Iwasaki H; Kawarabayashi T; Smith SK
Gynecol Oncol; 2004 Dec; 95(3):474-82. PubMed ID: 15581949
[TBL] [Abstract][Full Text] [Related]
8. Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma.
Sawada M; Tsuda H; Kimura M; Okamoto S; Kita T; Kasamatsu T; Yamada T; Kikuchi Y; Honjo H; Matsubara O
Cancer Sci; 2003 Nov; 94(11):986-91. PubMed ID: 14611676
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical evaluation of the c-kit proto-oncogene in sarcomas of the uterus: a case series.
Leath CA; Straughn JM; Conner MG; Barnes MN; Alvarez RD; Partridge EE; Huh WK
J Reprod Med; 2004 Feb; 49(2):71-5. PubMed ID: 15018431
[TBL] [Abstract][Full Text] [Related]
10. ERBB-2 gene overexpression and amplification in uterine sarcomas.
Amant F; Vloeberghs V; Woestenborghs H; Debiec-Rychter M; Verbist L; Moerman P; Vergote I
Gynecol Oncol; 2004 Dec; 95(3):583-7. PubMed ID: 15581967
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Lee SJ; Kim HS; Kim HS; Chun YK; Hong SR; Lee JH
Hum Pathol; 2007 Aug; 38(8):1226-31. PubMed ID: 17490723
[TBL] [Abstract][Full Text] [Related]
12. AKT, EGFR, C-ErbB-2, and C-kit expression in uterine carcinosarcoma.
Saglam O; Husain S; Toruner G
Int J Gynecol Pathol; 2013 Sep; 32(5):493-500. PubMed ID: 23896716
[TBL] [Abstract][Full Text] [Related]
13. Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer.
Ferrandina G; Ranelletti FO; Lauriola L; Fanfani F; Legge F; Mottolese M; Nicotra MR; Natali PG; Zakut VH; Scambia G
Gynecol Oncol; 2002 May; 85(2):305-10. PubMed ID: 11972392
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas.
Santin AD; Bellone S; Siegel ER; McKenney JK; Thomas M; Roman JJ; Burnett A; Tognon G; Bandiera E; Pecorelli S
Clin Cancer Res; 2007 Jun; 13(11):3339-46. PubMed ID: 17545541
[TBL] [Abstract][Full Text] [Related]
15. Sarcomatoid carcinoma of the upper urinary tract: clinical outcome and molecular characterization.
Wang X; MacLennan GT; Zhang S; Montironi R; Lopez-Beltran A; Tan PH; Foster S; Baldridge LA; Cheng L
Hum Pathol; 2009 Feb; 40(2):211-7. PubMed ID: 18799188
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of ovarian carcinosarcomas: a single institution experience.
Zorzou MP; Markaki S; Rodolakis A; Kastritis E; Bozas G; Dimopoulos MA; Papadimitriou CA
Gynecol Oncol; 2005 Jan; 96(1):136-42. PubMed ID: 15589592
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas.
Potti A; Ganti AK; Foster H; Knox S; Hebert BJ; Tendulkar K; Sholes K; Koch M; Kargas S
Anticancer Res; 2004; 24(1):333-7. PubMed ID: 15015617
[TBL] [Abstract][Full Text] [Related]
18. Expression of receptor tyrosine kinases in esophageal carcinosarcoma.
Sano A; Sakurai S; Kato H; Suzuki S; Yokobori T; Sakai M; Tanaka N; Inose T; Sohda M; Nakajima M; Fukai Y; Miyazaki T; Ojima H; Hosoya Y; Enomoto T; Kanda T; Ajioka Y; Kuwano H
Oncol Rep; 2013 Jun; 29(6):2119-26. PubMed ID: 23546020
[TBL] [Abstract][Full Text] [Related]
19. Molecular evidence that most but not all carcinosarcomas of the uterus are combination tumors.
Wada H; Enomoto T; Fujita M; Yoshino K; Nakashima R; Kurachi H; Haba T; Wakasa K; Shroyer KR; Tsujimoto M; Hongyo T; Nomura T; Murata Y
Cancer Res; 1997 Dec; 57(23):5379-85. PubMed ID: 9393763
[TBL] [Abstract][Full Text] [Related]
20. Placental site trophoblastic tumor: lymphatic spread and possible target markers.
Lan C; Li Y; He J; Liu J
Gynecol Oncol; 2010 Mar; 116(3):430-7. PubMed ID: 19910023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]